Pier Capital, LLC Myovant Sciences Ltd. Transaction History

Pier Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $2.29 Million - $4.33 Million	-294,954 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$11.38 - $16.4 $13,792 - $19,876	-1,212 Reduced 0.41%	294,954 $3.93 Million
Q4 2021 Feb 10, 2022	BUY	$14.31 - $23.87 $45,648 - $76,145	3,190 Added 1.09%	296,166 $4.61 Million
Q3 2021 Nov 10, 2021	SELL	$18.94 - $26.99 $144,701 - $206,203	-7,640 Reduced 2.54%	292,976 $6.57 Million
Q2 2021 Aug 12, 2021	SELL	$17.07 - $24.56 $4.34 Million - $6.24 Million	-254,163 Reduced 45.81%	300,616 $6.85 Million
Q1 2021 May 13, 2021	BUY	$20.46 - $25.18 $3.09 Million - $3.8 Million	150,940 Added 37.38%	554,779 $11.4 Million
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $1.39 Million - $2.79 Million	101,049 Added 33.37%	403,839 $11.2 Million
Q3 2020 Nov 13, 2020	BUY	$14.05 - $22.6 $4.25 Million - $6.84 Million	302,790 New	302,790 $4.25 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.